The evolution of prolactinomas in children and adolescents continues to be controversial. Girls have more prevalence of microprolactinomas and their signs and symptoms are related to hyperprolactinemia and the resulting hypogonadotrophic hypogonadism. In males, the greater incidence of macroadenomas results in the presence of neuro-ophthalmologic signs. The larger prevalence of macroadenomas in males is consistent with findings in adults and would not be related to a later diagnosis. In patients with asymptomatic hyperprolactinemia, the presence of altered proportions of PRL isoforms should be evaluated. The diagnosis of prolactinoma requires both radiographic evidence of pituitary adenoma and laboratory analysis documenting the presence of sustained hyperprolactinemia. Because of their effectiveness and tolerance, dopaminergic agonists are the initial therapy of choice in pediatric age patients. Finally, molecular biology and genetic studies have brought new insights into the pathogenesis, clinical behavior and different therapeutic responses.

Keywords:
Peripubertal prolactinomas, Pediatric hyperprolactinemia, Dopamine agonists, Hyperprolactinemia, Asymptomatic hyperprolactinemia
1.
Colao A, Lombardi G: Growth hormone and prolactin excess. Lancet 1998;352:1455–1461.
2.
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A: Guidelines of the pituitary of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265–273.
3.
De Menis E, Visentin A, Billeci D, Tramontin P, Agostini S, Marton E, Conte N: Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases. J Endocrinol Invest 2001;24:92–97.
4.
Partington MD, Davis DH, Laws ER Jr, Scheifhauer BW: Pituitary adenomas in childhood and adolescents. Results of transsphenoidal surgery. J Neurosurg 1994;80:209–216.
5.
Zhang X, Horwitz GA, Prezant TR, Valentín A, Nakashima M, Bronstein MD, Melmed S: Structure, expression, and function of human pituitary tumor-transforming gene. Mol Endocrinol 1999;13:156–166.
6.
Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418–422.
7.
Heancy AP, Horwitz GA, Wang Z, Singson R, Melmed S: Early involvement of estrogen-induced pituitary tumor-transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 1999;5:1317–1321.
8.
Zhang X, Horwith GA, Heanney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S: Pituitary tumor-transforming gene expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761–767.
9.
Gürlek A, Karavitaki N, Ansorge O, Wass JA: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 2007;156:143–153.
10.
Jaffrain-Rea ML, Petrangeli E, Lubrano C, Minniti G, Di Stefano D, Sciarra F, Frati L, Tamburrano G, Cantore G, Gulino Al: Epidermal growth factor binding sites in human pituitary macroadenomas. J Endocrinol 1998;7:45–50.
11.
Fedele M, Pierantoni GM, Visone R, Fusco A: Critical role of the HMGA2 gene in pituitary adenomas. Cell Cycle 2006;5:2045–2048.
12.
Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Winberg RA: Effects of an RB mutation in the mouse. Nature 1992;359:295–300.
13.
Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM, Oyesiku NM: Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary 2008;11:231–245.
14.
Fideleff HL, Boquete HR, Sequera A, Suárez M, Sobrado P, Giaccio A: Peripubertal prolacinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000;13:261–267.
15.
Stefaneanu L, Kovacs K, Horvath E, Lloyd RV, Buchfelder M, Fahlbusch R, Smyth H: In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. J Clin Endocrinol Metab 1994;78:83–88.
16.
Kadioglu P, Oral G, Sayitoglu M, Erensoy N, Senel B, Gazioglu N, Sav A, Cetin G, Ozbek U: Aromatase cytochrome P450 enzyme expression in human pituitary. Pituitary 2008;11:29–35.
17.
Burdman JA, Pauni M, Heredia Sereno GM, Bordón AE: Estrogen receptors in human pituitary tumors. Horm Metab Res 2008;40:524–527.
18.
Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G: Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777–2780.
19.
Melmed S, Kleinberg DL: Anterior pituitary; in Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds): Williams Textbook of Endocrinology. Philadelphia, Saunders, 2002, p 177.
20.
Galli-Tsinopoulou A, Nousia-Arvanitakis S, Mitsiakos G, Karamouzis M, Dimitriadis A: Osteopenia in children and adolescents with hyperprolactinemia. J Pediatr Endocrinol Metab 2000;13:439–441.
21.
Naliato ECO, Farias MLF, Violante AHD: Prolactinomas e densidade mineral óssea em homens. Arq Bras Endocrinol Metab 2005;49:183–195.
22.
Bussade I, Naliato ECO, Mendonça LMC, Violante AHD, Farias MLF: Redução da densidade mineral óssea em mulheres na menacme com prolactinoma. Arq Bras Endocrinol Metab 2007;51:1522–1527.
23.
Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G: Prolactinomas in adolescents: persistent bone loss after two years of prolactin normalization. Clin Endocrinol 2000;52:319–327.
24.
Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E, Zimmerman D: Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994;79:1135–1140.
25.
Semple P, Fieggen G, Parkes J, Levitt N: Giant prolactinomas in adolescence: an uncommon cause of blindness. Childs Nerv Syst 2007;23:213–217.
26.
Krassas GE, Pontikides N, Kaltsas T: Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Horm Res 1999;52:45–48.
27.
Fabre-Brue C, Roth E, Simonin G, Palix C, Martin PM, Brue T: Macroprolactinemia: a cause of hyperprolactinemia in childhood. J Pediatr Endocrinol Metab 1997;10:411–417.
28.
Fideleff HL, Ruibal G, Boquete H, Pujol A, Sequera A, Sobrado P: Macroprolactinemia in childhood and adolescence: a cause of asymptomatic hyperprolactinemia. Horm Res 2000;53:16–19.
29.
Sapin R, Kertesz G: Macroprolactin detection by precipitation with protein A-Sepharose: a rapid screening method compared with polyethylene glycol precipitation. Clin Chem 2003;49:502–505.
30.
Smith TP, Kavanagh L, Healy ML, McKenna J: Technology insight: measuring prolactin in clinical sample. Nat Clin Pract Endocrinol Metab 2007;3:279–289.
31.
Fideleff HL, Azaretzky M, Boquete HR, Pujol AB, Honfi M, Suárez MG, Fideleff G, Giaccio AV: Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test J Pediatr Endocrinol Metab 2003;16:163–167.
32.
Chahal J, Schlechte J: Hyperprolactinemia. Pituitary 2008;11:141–146.
33.
Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485–534.
34.
Gillam MP, Fideleff H, Boquete HR, Molitch ME: Prolactin excess: treatment and toxicity. Pediatr Endocrinol Rev 2004;2:108–114.
35.
Colao A, Lombardi G, Annunziato L: Cabergoline. Expert Opin Pharmacother 2000;1:555–574.
36.
Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM: Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J 1984;289:1101–1103.
37.
Le Feuvre CM, Isaacs AJ, Frank OS: Bromocriptine-induced psychosis in acromegaly. Br Med J 1982;285:1315.
38.
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007;356:39–46.
39.
Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM: Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008;93:3348–3356.
40.
Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D’Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G: Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3777–3784.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.